Trulicity Cost vs. Alternatives: How Dulaglutide Compares to Other GLP-1s

How Trulicity Works as a GLP-1 Receptor Agonist

Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing a modified GLP-1 analogue to a human IgG4-Fc fragment, which slows renal clearance and extends the half-life to approximately 5 days. This design supports once-weekly dosing. The drug binds to GLP-1 receptors on pancreatic beta cells, amplifying glucose-dependent insulin secretion while suppressing glucagon release from alpha cells when blood sugar is elevated 1.

The glucose-dependent mechanism is clinically significant. Because insulin release ramps up only when blood glucose rises above normal thresholds, the standalone hypoglycemia risk stays low. Dulaglutide also slows gastric emptying and acts on hypothalamic appetite centers, which contributes to modest weight loss in most patients. These pharmacologic properties are shared across the GLP-1 receptor agonist class, though structural differences between agents translate into measurable gaps in potency and clinical outcomes.

The 2024 American Diabetes Association (ADA) Standards of Care list GLP-1 RAs as preferred second-line therapy after metformin for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk 2. Dulaglutide, semaglutide, and liraglutide each carry FDA-approved labeling for cardiovascular risk reduction, a distinction that exenatide extended-release does not hold.

Trulicity Pricing in Context

The list price for Trulicity sits near $1,000 per month at the wholesale acquisition level, a figure consistent across the four available dose strengths (0.75 mg, 1.5 mg, 3.0 mg, 4.5 mg). Net cost after rebates varies by insurer. Patients with commercial insurance and manufacturer copay cards may pay as little as $25 per fill, while uninsured patients face close to the full WAC 3.

This pricing is not an outlier for the class. Ozempic (semaglutide injectable) lists at roughly $936 to $1,029 per month. Mounjaro (tirzepatide) carries a WAC of approximately $1,023 to $1,069 depending on the dose. Rybelsus (oral semaglutide) lists near $936 per month for the 14 mg tablet strength. Victoza (liraglutide 1.8 mg daily) runs approximately $1,100 per month, though its older patent status has prompted some payers to restrict access in favor of newer weekly agents.

The practical question is rarely "which drug costs less at list price" but rather "which drug does my formulary prefer." Payer negotiations, rebate contracts, and step-therapy requirements create large gaps between WAC and actual out-of-pocket cost. A patient whose plan places Trulicity on a preferred tier may pay $30 per month, while the same patient switching to a non-preferred Ozempic could face $150 or more. Formulary position, not list price, determines real-world affordability for most insured Americans 4.

Head-to-Head Efficacy: Trulicity vs. Ozempic

The SUSTAIN 7 trial (N=1,201) directly compared dulaglutide and semaglutide in patients with type 2 diabetes inadequately controlled on metformin. At 40 weeks, semaglutide 0.5 mg reduced A1c by 1.5% versus 1.1% for dulaglutide 0.75 mg. At the higher doses, semaglutide 1.0 mg achieved a 1.8% A1c reduction compared with 1.4% for dulaglutide 1.5 mg 5.

Weight loss also favored semaglutide. Patients on semaglutide 1.0 mg lost a mean of 6.5 kg versus 3.0 kg for dulaglutide 1.5 mg over the same period. These differences were statistically significant and have shaped prescribing patterns, particularly for patients who prioritize weight reduction alongside glycemic control.

The gap narrows somewhat when Trulicity's higher dose strengths (3.0 mg and 4.5 mg, approved in 2020) enter the comparison. The AWARD-11 trial demonstrated that dulaglutide 4.5 mg reduced A1c by 1.9% at 36 weeks, approaching the magnitude seen with semaglutide 1.0 mg, though no direct head-to-head trial compares dulaglutide 4.5 mg to semaglutide 6. Weight loss with dulaglutide 4.5 mg reached approximately 4.7 kg, still below semaglutide 1.0 mg results in cross-trial comparisons.

Dr. John Buse, Director of the Diabetes Center at the University of North Carolina, has noted: "When semaglutide and dulaglutide are available at similar out-of-pocket cost, the glycemic and weight data tend to favor semaglutide, but formulary access and patient preference for device design still make dulaglutide a strong choice for many patients."

Head-to-Head Efficacy: Trulicity vs. Mounjaro

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist, giving it a pharmacologically distinct mechanism from dulaglutide. The SURPASS-2 trial (N=1,879) compared tirzepatide at 5 mg, 10 mg, and 15 mg doses against semaglutide 1.0 mg rather than dulaglutide directly 7. Tirzepatide 15 mg reduced A1c by 2.5% versus 1.9% for semaglutide 1.0 mg at 40 weeks. Body weight loss was 12.4 kg with tirzepatide 15 mg compared to 6.2 kg with semaglutide 1.0 mg.

No published randomized trial compares tirzepatide directly to dulaglutide, but given that semaglutide outperforms dulaglutide in SUSTAIN 7 and tirzepatide outperforms semaglutide in SURPASS-2, the indirect comparison strongly favors tirzepatide for both glycemic and weight outcomes.

The cost calculus changes when Mounjaro lacks formulary coverage. Patients may face step-therapy requirements mandating a trial of Trulicity or Ozempic before gaining access to tirzepatide. In these cases, Trulicity's broader commercial formulary presence can make it the pragmatic first-line GLP-1 RA, even if tirzepatide would be the pharmacologically preferred agent.

Trulicity vs. Victoza and Other Older GLP-1 RAs

Liraglutide (Victoza) requires daily injection at 1.8 mg for type 2 diabetes, an administration burden that drives many patients toward weekly options. The AWARD-6 trial (N=599) compared dulaglutide 1.5 mg weekly to liraglutide 1.8 mg daily and found non-inferior A1c reduction (1.42% vs. 1.36%) at 26 weeks, with similar weight loss of approximately 3 kg in both arms 8. Dulaglutide's once-weekly convenience without sacrifice in efficacy made it the practical upgrade for patients previously on liraglutide.

Exenatide extended-release (Bydureon BCise) is another weekly GLP-1 RA but has consistently shown lower A1c reductions in head-to-head data. The AWARD-1 trial found dulaglutide 1.5 mg superior to exenatide 2 mg weekly, with A1c reductions of 1.51% versus 0.99% at 26 weeks 9. Bydureon also lacks a cardiovascular outcome trial showing MACE reduction, making it a less attractive option for higher-risk patients.

Rybelsus (oral semaglutide) offers a different value proposition: no injection at all. The oral formulation at 14 mg daily reduces A1c by approximately 1.3% and produces modest weight loss of 3 to 4 kg. For patients who refuse injectable therapy, Rybelsus becomes the default GLP-1 RA regardless of cost, though adherence to its strict empty-stomach dosing requirements (taken 30 minutes before food, with no more than 4 ounces of plain water) can be challenging 10.

Cardiovascular Outcomes: Where Trulicity Stands

The REWIND trial (N=9,901) is Trulicity's defining cardiovascular dataset. Published in The Lancet in 2019, it enrolled patients with type 2 diabetes at a lower baseline cardiovascular risk than most prior GLP-1 RA outcome trials (only 31% had established cardiovascular disease at enrollment). Over a median follow-up of 5.4 years, dulaglutide 1.5 mg reduced the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 12% versus placebo (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026) 11.

This result is notable because it extends the cardiovascular benefit signal to a broader diabetic population, not just those with pre-existing heart disease. The 2024 ADA Standards of Care reference REWIND alongside SUSTAIN-6 (semaglutide) and LEADER (liraglutide) as evidence supporting GLP-1 RA use for cardiovascular risk reduction 2.

The SUSTAIN-6 trial (N=3,297) demonstrated a 26% reduction in MACE with semaglutide over 2.1 years of follow-up, a larger relative risk reduction than REWIND's 12% 12. However, the SUSTAIN-6 population carried higher baseline cardiovascular risk (83% with established CVD or chronic kidney disease), making direct comparison of the relative risk reductions between the two trials unreliable. Both agents hold FDA-approved cardiovascular indications.

Dr. Hertzel Gerstein, the REWIND principal investigator at McMaster University, stated: "REWIND showed that the cardiovascular benefits of dulaglutide extend to the broad population of people with type 2 diabetes, including those who have risk factors but have not yet had a cardiovascular event."

Insurance and Formulary Considerations

Formulary dynamics shift annually and vary by plan type. In 2025 and 2026, several large pharmacy benefit managers (PBMs) have placed Mounjaro on preferred tiers for type 2 diabetes while moving Trulicity to non-preferred status in some commercial plans, reversing patterns from prior years. Medicare Part D coverage for all GLP-1 RAs in the diabetes indication remains available, though tier placement and prior authorization requirements differ across plan sponsors 4.

Patients without insurance face a harder calculation. Eli Lilly's Trulicity Savings Card offers up to $150 off per fill for eligible commercially insured patients. The Lilly Cares Foundation provides free medication to qualifying low-income, uninsured individuals. Novo Nordisk and Eli Lilly run similar programs for Ozempic and Mounjaro, respectively, so manufacturer assistance alone rarely creates a definitive cost advantage for one agent over another.

The one structural cost change to watch: dulaglutide's primary patent expires in 2027. If biosimilar manufacturers enter the market on schedule, dulaglutide could become the first GLP-1 RA with a lower-cost biosimilar option, potentially reducing prices by 15% to 40% based on patterns observed in other biologic classes 13.

Choosing the Right GLP-1 RA: A Decision Framework

The ADA does not rank individual GLP-1 receptor agonists against each other. Instead, the 2024 Standards of Care recommend selecting based on cardiovascular benefit evidence, weight loss goals, route of administration, cost, and patient preference 2.

A practical framework for clinicians:

When Trulicity may be the best fit: The patient's formulary places dulaglutide on a preferred tier with low copay. The patient has type 2 diabetes with cardiovascular risk factors (REWIND population). Glycemic targets can be met with A1c reductions of 1.0% to 1.9%. Weight loss of 3 to 5 kg is acceptable. The patient prefers a simple, pre-filled, single-use pen that does not require needle attachment.

When Ozempic may be preferred: Greater A1c lowering or weight loss is a priority. The formulary favors semaglutide. The patient does not have strong device-design preferences.

When Mounjaro may be preferred: Maximal A1c reduction (up to 2.5%) and weight loss (up to 12 kg) are primary goals. The patient has formulary access or can obtain prior authorization. Dual GIP/GLP-1 mechanism is desired.

When Rybelsus may be preferred: The patient declines injectable therapy entirely. Adherence to the oral dosing protocol is feasible.

Cost-Effectiveness Evidence

A 2023 Institute for Clinical and Economic Review (ICER) analysis evaluated the cost-effectiveness of GLP-1 RAs for type 2 diabetes. The report found that at current net prices, dulaglutide, semaglutide, and tirzepatide all exceeded conventional willingness-to-pay thresholds of $100,000 to $150,000 per quality-adjusted life-year (QALY) when compared to older generic therapies like sulfonylureas or DPP-4 inhibitors 14. The cardiovascular and renal benefits of GLP-1 RAs improved their cost-effectiveness ratios when analyses were restricted to high-risk populations, but none of the branded agents achieved cost-effectiveness at list prices for the average type 2 diabetes patient.

This finding underscores the importance of net pricing and formulary negotiation. The clinical evidence for GLP-1 RAs is strong across the class, but affordability remains the primary barrier to uptake. An estimated 20% to 30% of GLP-1 RA prescriptions are abandoned at the pharmacy due to cost, a rate higher than most other diabetes drug classes 15.

Dulaglutide's potential biosimilar entry in 2027 or 2028 could meaningfully shift this equation. A biosimilar priced 30% below Trulicity's current WAC would bring the monthly cost to approximately $690 to $720, still above oral generics but closer to price points where cost-effectiveness models become favorable for broader populations.